The role of gemcitabine in the treatment of other tumours
1998
Gemcitabine in the Treatment of Various Tumors
publication
Evidence: moderate
Author Information
Author(s): J Carmichael
Primary Institution: CRC Department of Clinical Oncology, Nottingham City Hospital Trust
Hypothesis
Gemcitabine may be effective against a range of human solid tumors beyond its approved uses.
Conclusion
Gemcitabine has shown significant activity against various malignancies and is well tolerated by patients.
Supporting Evidence
- Gemcitabine has been shown to have significant activity in non-small-cell lung cancer and pancreatic cancer.
- Response rates of around 20% were observed in studies of single-agent gemcitabine for NSCLC.
- Combination therapy with gemcitabine and cisplatin has resulted in response rates of approximately 50% in NSCLC.
- Gemcitabine has demonstrated activity in breast cancer, bladder cancer, ovarian cancer, and small-cell lung cancer.
Takeaway
Gemcitabine is a medicine that helps treat different types of cancer, and it usually doesn't make people feel very sick.
Methodology
The study involved reviewing clinical trials and patient responses to gemcitabine in various cancers.
Limitations
The study primarily focuses on early phase trials, which may not fully represent long-term outcomes.
Want to read the original?
Access the complete publication on the publisher's website